# CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia

> **NCT04785833** · NA · UNKNOWN · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- T-ALL

## Interventions

- **DRUG:** T cell injection targeting CD7 chimeric antigen receptor

## Key facts

- **NCT ID:** NCT04785833
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-04
- **Primary completion:** 2022-04-30
- **Final completion:** 2024-02-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04785833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04785833, "CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04785833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*